# US 2022/0033457 A1 · Treatment of neurological diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033457 A1
- Document ID: US20220033457A1
- Status: Published application
- Kind: A1
- Application number: 17/500,430
- Filed: 2021-10-13
- Published: 2022-02-03
- Earliest claimed: 2016-12-05
- Assignees: Lancaster University Business Enterprises Limited
- Applicants: Lancaster University Business Enterprises Limited
- Inventors: Christian Hölscher
- Web page: https://patentgrep.com/patent/US20220033457A1

## CPC

- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K 14/605: Glucagons
- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Aspects and embodiments of the present invention relate to the treatment of neurological disorders such as for example, Alzheimers disease and Parkinsons disease. Particularly, certain embodiments relate to GIP/GLP-1 co-agonist peptides for use in the treatment of these two neurological disorders. Also included in the present invention are inter alia pharmaceutical compositions comprising the GIP/GLP-1 co-agonist peptides, together with methods of treating such disorders as well as other subject matter.

## Claims

### Claim 1

A glucose-dependent insulinotropic peptide/glucagon-like peptide 1 (GIP/GLP-1) co-agonist peptide, which consists of the amino acid sequence of:
YXEGTFTSDYSIYLDKQAAXEFVNWLLAGGPSSGAPPPSKKKKKK-NH2 (SEQ. ID. No. 11) wherein X=aminoisobutyric acid, or which consists of the amino acid sequence of:
YXEGTFTSDYSIYLDKQAAXEFVNWLLAGGPSSGAPPPSKRRQRRKKRGY-NH2 (SEQ. ID. No. 12) wherein X=aminoisobutyric acid,
wherein a hydrophilic moiety is covalently linked to an amino acid of said peptide or wherein said peptide is conjugated with a lipophilic substituent.

### Claim 2 (depends on 1)

The peptide according to claim 1, wherein a hydrophilic moiety is covalently linked to (i) an amino acid at position 24 or (ii) an amino acid at position 39 or 40.

### Claim 3 (depends on 1)

The peptide according to claim 1, wherein a hydrophilic moiety is covalently linked to (i) an amino acid at position 24 or (ii) an amino acid at position 39 or 40, wherein said hydrophilic moiety is a water-soluble polymer.

### Claim 4 (depends on 1)

The peptide according to claim 1, wherein said lipophilic substituent comprises an acyl group.

### Claim 5 (depends on 4)

The peptide according to claim 4, wherein said lipophilic substituent comprising an acyl group is a fatty acid molecule selected from a C-8 octanoyl group, a C-10 decanoyl group, a C-12 lauroyl group, a C-14 myristoyl group, a C-16 palmitoyl group, a C-18 stearoyl group and a C-20 acyl group.

### Claim 6 (depends on 1)

The peptide according to claim 1, wherein the peptide is conjugated with a lipophilic substituent, which is attached to an amino acid at the carboxyl-terminus of the peptide.

### Claim 7 (depends on 1)

The peptide according to claim 1, wherein a spacer conjugates the lipophilic substituent to the peptide.

### Claim 8 (depends on 7)

The peptide according to claim 7, wherein said spacer is a residue from a naturally occurring or unnatural amino acid, selected from the group consisting of Gly, Pro, Ala, Val, Leu, Ile, Met, Cys, Phe, Tyr, Trp, His, Lys, Arg, Gln, Asn, α-Glu, γ-Glu, ε-Lys, Asp, Ser, Thr, Gaba, Aib, β-aminohexonyl, 7-aminoheptanoyl, 8-aminooctanoyl, 9-aminononanoyl, 10-aminodecanoyl or 8-amino-3,6-dioxaoctanoyl.

### Claim 9 (depends on 1)

The peptide according to claim 1, wherein the peptide is conjugated by a spacer, wherein said spacer is γ-Glu or wherein the spacer is a dipeptide.

### Claim 10

A pharmaceutically acceptable salt or solvate of a glucose-dependent insulinotropic peptide/glucagon-like peptide 1 (GIP/GLP-1) co-agonist peptide which consists of the amino acid sequence of:
(SEQ. ID. No. 11)
YXEGTFTSDYSIYLDKQAAXEFVNWLLAGGPSSGAPPPSKKKKKK-NH2
wherein X=aminoisobutyric acid, or which consists of the amino acid sequence of:
(SEQ. ID. No. 12)
YXEGTFTSDYSIYLDKQAAXEFVNWLLAGGPSSGAPPPSKRRQRRKK
RGY-NH2
wherein X=aminoisobutyric acid.

### Claim 11 (depends on 10)

The pharmaceutically acceptable salt or solvate according to claim 10, wherein a hydrophilic moiety is covalently linked to an amino acid.

### Claim 12 (depends on 10)

The pharmaceutically acceptable salt or solvate according to claim 10, wherein a hydrophilic moiety is covalently linked to (i) an amino acid at position 24 or (ii) an amino acid at position 39 or 40.

### Claim 13 (depends on 10)

The pharmaceutically acceptable salt or solvate according to claim 10, wherein a hydrophilic moiety is covalently linked to (i) an amino acid at position 24 or (ii) an amino acid at position 39 or 40, wherein said hydrophilic moiety is a water-soluble polymer.

### Claim 14 (depends on 10)

The pharmaceutically acceptable salt or solvate according to claim 10, wherein the peptide is conjugated with a lipophilic substituent.

### Claim 15 (depends on 14)

The pharmaceutically acceptable salt or solvate according to claim 14, wherein the lipophilic substituent is a fatty acid molecule is selected from a C-8 octanoyl group, a C-10 decanoyl group, a C-12 lauroyl group, a C-14 myristoyl group, a C-16 palmitoyl group, a C-18 stearoyl group and a C-20 acyl group.

### Claim 16 (depends on 10)

The pharmaceutically acceptable salt or solvate according to claim 10, wherein the peptide is conjugated to a lipophilic substituent through a spacer.

### Claim 17 (depends on 16)

The pharmaceutically acceptable salt or solvate according to claim 16, wherein the spacer is a residue from a naturally occurring or unnatural amino acid, wherein the spacer comprises a residue of Gly, Pro, Ala, Val, Leu, Ile, Met, Cys, Phe, Tyr, Trp, His, Lys, Arg, Gln, Asn, α-Glu, γ-Glu, ε-Lys, Asp, Ser, Thr, Gaba, Aib, β-aminohexonyl, 7-aminoheptanoyl, 8-aminooctanoyl, 9-aminononanoyl, 10-aminodecanoyl or 8-amino-3,6-dioxaoctanoyl.

### Claim 18

A method for treatment and/or prevention of the progression of a neurological disorder selected from the group consisting of Alzheimers Disease and Parkinsons disease in a subject in need thereof, comprising administering to the subject a glucose-dependent insulinotropic peptide/glucagon-like peptide 1 (GIP/GLP-1) co-agonist peptide, which consists of the amino acid sequence of:
(SEQ. ID. No. 11)
YXEGTFTSDYSIYLDKQAAXEFVNWLLAGGPSSGAPPPSKKKKKK-NH2
wherein X=aminoisobutyric acid, or
which consists of the amino acid sequence of:
(SEQ. ID. No. 12)
YXEGTFTSDYSIYLDKQAAXEFVNWLLAGGPSSGAPPPSKRRQRRKK
RGY-NH2
wherein X=aminoisobutyric acid, or
a pharmaceutically acceptable salt or solvate thereof.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the peptide comprises a hydrophilic moiety covalently linked to an amino acid.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the peptide is conjugated with a lipophilic substituent.
